National Institute of Allergy and Infectious Disease (NIAID) Funding for Studies of Hospital-Associated Bacterial Pathogens: Are Funds Proportionate to Burden of Disease?

Antimicrobial Resistance and Infection Control

Volumn 1, Issue , 2012, Pages

  Kwon, Seunghyug ^a,b   Schweizer, Marin L ^a,b,c   Perencevich, Eli N ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antibiotic resistance; disease burden; Hospital associated infection; NIH; research funding

Indexed keywords

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECONOMIC EVALUATION; ENTEROCOCCUS FAECIUM; FUNDING; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; MEDICAL SOCIETY; MORTALITY; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84861058968     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/2047-2994-1-5     Document Type: Article

References (22)

1. Istook E. Research funding on major diseases is not proportionate to taxpayers' needs. J NIH Res 1997, 9(8):26-8.
2. Anderson C. NIH budget: A new kind of earmarking. Science 1993, 260(5107):483.
3. Marshall E. Lobbyists seek to reslice NIH's pie. Science 1997, 276(5311):344-6. 10.1126/science.276.5311.344, 9139352.
4. National Institutes of Health Working Group on Priority Setting Setting research priorities at the National Institutes of Health. 1997, Bethesda, MD: National Institutes of Health, National Institutes of Health Working Group on Priority Setting.
5. Committee on NIH Research Priority-Setting Process Scientific opportunities and public needs: Improving priority setting and public input at the national institutes of health. 1998, Committee on NIH Research Priority-Setting Process.
6. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007, 122(2):160-6. 1820440, 17357358.
7. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE, . Society for Healthcare Epidemiology of America Raising standards while watching the bottom line: Making a business case for infection control. Infect Control Hosp Epidemiol 2007, 28(10):1121-33. 10.1086/521852, 17933084, Society for Healthcare Epidemiology of America.
8. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008, 197(8):1079-81. 10.1086/533452, 18419525.
9. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final data for 2007. National vital statistics reports. 2010, Hyattsville, MD: National Center for Health Statistics.
10. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, . Active Bacterial Core surveillance (ABCs) MRSA Investigators Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298(15):1763-71. 10.1001/jama.298.15.1763, 17940231, Active Bacterial Core surveillance (ABCs) MRSA Investigators.
11. National Institutes of Health National Institute of Allergy and Infectious Diseases Congresional justification. 2008, Bethesda, MD: National Institutes of Health, National Institutes of Health National Institute of Allergy and Infectious Diseases.
12. Centers for Disease Control and Prevention HIV surveillance report. 2008, Centers for Disease Control and Prevention., http://www.cdc.gov/hiv/topics/surveillance/resources/reports/
13. Wenzel RP. The antibiotic pipeline--challenges, costs, and values. N Engl J Med 2004, 351(6):523-6. 10.1056/NEJMp048093, 15295041.
14. Projan SJ. Why is big pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol 2003, 6(5):427-30. 10.1016/j.mib.2003.08.003, 14572532.
15. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'Doye B, Pittet D, Richtmann R, Seto WH, van der Meer JW, Voss A. Society's failure to protect a precious resource: Antibiotics. Lancet 2011, 378(9788):369-71. 10.1016/S0140-6736(11)60401-7, 21477855.
16. Burr CK, Lampe MA, Corle S, Margolin FS, Abresh C, Clark J, . National Organizations' Collaborative to Eliminate Perinatal HIV in the US An end to perinatal HIV: Success in the US requires ongoing and innovative efforts that should expand globally. J Public Health Policy 2007, 28(2):249-60. 10.1057/palgrave.jphp.3200126, 17585325, National Organizations' Collaborative to Eliminate Perinatal HIV in the US.
17. Long EF, Owens DK. The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine 2011, 29(36):6113-24. 10.1016/j.vaccine.2011.04.013, 21510996.
18. Bancroft EA. Antimicrobial resistance: It's not just for hospitals. JAMA 2007, 298(15):1803-4. 10.1001/jama.298.15.1803, 17940239.
19. Peters NK, Dixon DM, Holland SM, Fauci AS. The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis 2008, 197(8):1087-93. 10.1086/533451, 18419527.
20. FY2009 budget submission center for disease control and prevention discretionary all-purpose table [Internet]. Available from: http://www.cdc.gov/fmo/fmofybudget.htm.
21. Agency for Healthcare Research and Quality AHRQ's efforts to prevent and reduce healthcare-associated infections: FY2009 projects. Rockville, MD: Agency for Healthcare Research and Quality, Agency for Healthcare Research and Quality.
22. Panangala SV. U.S. Congressional Research Service. Veterans medical care: FY2009 appropriations (RL34598; July 29, 2008)